Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07148089 · ClinicalTrials.gov registry record · Phase 1
A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
A Phase 1 study of Catecholaminergic Polymorphic Ventricular Tachycardia, sponsored by Solid Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 5
- Study locations
NCT07148089: Recruiting Phase 1 study of Catecholaminergic Polymorphic Ventricular Tachycardia, sponsored by Solid Biosciences.
NCT07148089 is a Phase 1 study of Catecholaminergic Polymorphic Ventricular Tachycardia that is actively recruiting participants, run by Solid Biosciences. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07148089, a Phase 1 study of Catecholaminergic Polymorphic Ventricular Tachycardia, is actively recruiting participants, sponsored by Solid Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a Phase 1b, Multicenter, Open-Label, Dose Finding Study to Investigate the Safety and Tolerability of a Single Intravenous Dose of SGT-501 in participants with catecholaminergic polymorphic ventricular tachycardia (CPVT). The first-in-human (FIH) safety study will focus on obtaining safety data in adult participants. Cohort 1 and Cohort 2 (optional for dose exploration) will include participants ≥ 18 years of age. Cohort 3 will include participants ≥ 7 to \< 18 years of age and will be initiated following data and safety monitoring board (DSMB) recommendations. Participants will be monitored for 5 years post-administration of SGT-501 including the active treatment period (1 year) and long-term follow-up (LTFU) (4 years) period.
Conditions Studied
Interventions
- DRUG SGT-501
Study Locations (5)
Massachusetts
- Boston Children's Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- University of Pennsylvania - Philadelphia
British Columbia
- St. Paul's Hospital - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-02-23 |
| Est. Completion | 2031-05 |
| Phase | Phase 1 |
What NCT07148089 shows while recruiting
NCT07148089 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Catecholaminergic Polymorphic Ventricular Tachycardia appearing as the primary indexed condition, and to 1 intervention - of which SGT-501 is the first listed.
NCT07148089 lists 5 locations in 5 states (Massachusetts, Minnesota, Ohio).
Frequently Asked Questions
What is clinical trial NCT07148089 about?
NCT07148089 is a clinical study titled "A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)". This is a Phase 1b, Multicenter, Open-Label, Dose Finding Study to Investigate the Safety and Tolerability of a Single Intravenous Dose of SGT-501 in participants with catecholaminergic polymorphic ventricular tachycardia (CPVT). The first-in-human (FIH) safety study will focus on obtaining safety d...
What is the current status of trial NCT07148089?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2026-02-23. Estimated completion is 2031-05.
What conditions does trial NCT07148089 study?
This clinical trial studies the following conditions: Catecholaminergic Polymorphic Ventricular Tachycardia.
What interventions are being tested in trial NCT07148089?
The interventions under investigation include: SGT-501 (DRUG).
Who is sponsoring clinical trial NCT07148089?
This trial is sponsored by Solid Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07148089 being conducted?
This trial has 5 study locations across Massachusetts, Minnesota, Ohio, Pennsylvania, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Catecholaminergic Polymorphic Ventricular Tachycardia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07148089's enrollment target sits among peer trials
18 1721st of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI